Subscribe
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
2021
2020
2019
ASCO 2021 - Breast Cancer
ASCO 2021 Wrap-Up - Breast Cancer
ASCO 2020 - Lung Cancer
ASCO 2020 - Wrap Up
ASH 2020 - Multiple Myeloma
SABCS 2020 Highlights
ASH 2019 Post Wrap-Up
ASH 2019 Multiple Myeloma
Liquid Biopsy Compared with Tissue Biopsy for Molecular Profiling in Patients with NSCLC
ASCO 2020 - Wrap Up
Conference Correspondent
In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time.
Read More ›
Efficacy of Amivantamab (JNJ-61186372) in Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation
ASCO 2020 - Wrap Up
Conference Correspondent
Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with
EGFR
exon20ins-mutated non–small-cell lung cancer.
Read More ›
Barriers to Targeted Therapies for NSCLC Patients with Highly Actionable Gene Variants in the Veterans Health Affairs Program
ASCO 2020 - Wrap Up
Conference Correspondent
A substantial minority of patients with advanced non–small-cell lung cancer and highly actionable gene variants were not prescribed available targeted therapies in the Veterans Health Affairs National Precision Oncology Program.
Read More ›
Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC
ASCO 2020 - Lung Cancer
Conference Correspondent
Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Read More ›
Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors
ASCO 2020 - Lung Cancer
Conference Correspondent
The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented.
Read More ›
Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade
ASCO 2020 - Lung Cancer
Conference Correspondent
The characteristics of long-term responders to PD-1 blockade are presented.
Read More ›
Smoking Cessation and Lung Cancer: Recent Quitters Benefit Too
ASCO 2020 - Lung Cancer
Conference Correspondent
For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit.
Read More ›
Weekly Epirubicin as Second-Line Therapy for Malignant Pleural Mesothelioma
ASCO 2020 - Lung Cancer
Conference Correspondent
Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy.
Read More ›
ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC
ASCO 2020 - Lung Cancer
Conference Correspondent
Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population.
Read More ›
Cediranib Combined with Olaparib Is Active in Patients with Platinum-Pretreated SCLC
ASCO 2020 - Lung Cancer
Conference Correspondent
Patients with platinum-pretreated small-cell lung cancer may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor.
Read More ›
Page 9 of 31
4
5
6
7
8
9
10
11
12
13
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION